Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-Controlled Phase 2a Trial of GRI-0621 in Patients With Chronic Liver Disease

Next Previous
X
Search
Trial Profile

A Double-blind, Randomized, Placebo-Controlled Phase 2a Trial of GRI-0621 in Patients With Chronic Liver Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazarotene (Primary)
  • Indications Hepatitis B; Hepatitis C; Liver disorders; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms GRI-201
  • Sponsors GRI Bio

    • Most Recent Events

    • 21 Apr 2023 According to Vallon media release, data is expected in the Q2 of 2024.
    • 07 Aug 2019 Status changed from active, no longer recruiting to discontinued.
    • 17 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top